Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL300 (Clazakizumab) in End Stage Kidney Disease Undergoing Dialysis
NCT05485961Phase 3Recruiting
- Sponsor
- CSL Limited
- Start
- Apr 2024
- Primary completion
- May 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 35
01
Overview
Phase 3, randomised, double-blind trial of clazakizumab in Kidney disease (6 arms), sponsored by CSL Limited. Primary endpoints: Change from Baseline in high-sensitivity C-reactive protein at 12 weeks and Time to first occurrence of CV death or myocardial infarction at 5 years. Started Apr 2024; status: recruiting.
02
Drugs
clazakizumab
03
Conditions
Kidney disease
Beyond the preview
Go deeper on NCT05485961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05485961.